Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

• Published in: Blood Vol. 115; no. 14; pp. 2740 - 2748
• Main Authors: Stork, Linda C., Matloub, Yousif, Broxson, Emmett, La, Mei, Yanofsky, Rochelle, Sather, Harland, Hutchinson, Ray, Heerema, Nyla A., Sorrell, April D., Masterson, Margaret, Bleyer, Archie, Gaynon, Paul S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.04.2010; American Society of Hematology
• Series: Clinical Trials and Observations
• Subjects: Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Child; Child, Preschool; Clinical Trials and Observations; Female; Hepatic Veno-Occlusive Disease - chemically induced; Humans; Hypertension, Portal - chemically induced; Infant; Injections, Spinal; Male; Mercaptopurine - administration & dosage; Mercaptopurine - adverse effects; Methotrexate - administration & dosage; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Thioguanine - administration & dosage; Thioguanine - adverse effects
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2009-07-230656

The Children's Cancer Group 1952 (CCG-1952) clinical trial studied the substitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (ITT) for intrathecal methotrexate (IT-MTX) in the treatment of standard-risk acute lymphoblastic leukemia. After remission ind...